EGFR and lung cancer: In the current guidelines for the management of patients with non-curatively treated lung cancer, the liquid biopsy has found its way into the routine diagnostics for EGFR-mutated tumors, once the disease has progressed under a non-T790 M-addressing EGFR tyrosine kinase inhibitor [11].